Equity Details
Price & Market Data
Price: $4.08
Daily Change: +$0.02 / 0.49%
Daily Range: $3.90 - $4.25
Market Cap: $34,028,076
Daily Volume: 24,485
Performance Metrics
1 Week: -0.24%
1 Month: -8.83%
3 Months: 18.68%
6 Months: -24.08%
1 Year: 120.9%
YTD: -14.49%
About Evaxion A/S (EVAX)
Quick facts and data for Evaxion A/S (EVAX). Price: 4.08, daily change: +$0.02 / 0.49%. Market cap: 34,028,076. Performance across all periods.
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country: Denmark
Details
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
